• About us
• Contact

Advertisement

Organisation › Details

Galderma S.A.

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company has a presence in 65 countries with over 1000 sales representatives and is committed to improving the health of skin with an extensive line of products that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, medical solutions for skin senescence and skin cancer. With a new research and development center in Sophia Antipolis, France Galderma has one of the largest R&D facilities dedicated exclusively to dermatology. Leading dermatology brands include Differin(R), Rozex(R)/Metro(R), Clobex(R), Tri-Luma(R), Loceryl(R) and Cetaphil(R). Recently launched products include Pliaglis(R), a topical anaesthetic for dermatologic procedures in the United States, Epiduo(R), an innovative combination product for the treatment of acne in Europe and Argentina and Dysport(R), an injectable neuromodulator for the correction of wrinkles in Brazil and Argentina. *

 

	Start	1981-01-01 established jv
	Group	Nestlé (Group)
	Today	Galderma (Group)
	Industry	dermatic
	Region	Zug ZG
	Country	Switzerland
	Street	10 Zählerweg
	City	6300 Zug
		Address record changed: 2023-07-12
Basic data	Employees	F: 1,001 to 5,000 (2011-08-14)
	Currency	EUR
	Annual sales	1,203,500,000 (sales (2010) 2010-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-12

Advertisement

More documents for Nestlé (Group)

• [1] Recipharm AB. (11/21/23). "Press Release: Marc Funk to Transition to Recipharm's Board of Directors; Greg Behar Appointed New CEO; Inhaled Business to Standalone in 2024"....
• [2] Enterome S.A.. (7/18/22). "Press Release: Enterome Signs Major Strategic R&D Collaboration with Nestlé Health Science to Develop and Commercialize New AllerMimics and EndoMimics Immunotherapies for Food Allergies and Inflammatory Bowel Disease". Paris....
• [3] Seres Therapeutics, Inc.. (7/1/21). "Press Release: Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement". Cambridge, MA & Lausanne....
• [4] ECBF Management GmbH. (12/15/20). "Press Release: The European Circular Bioeconomy Fund Welcomes Nestlé as an Investor to Accelerate Sustainable Innovation in Europe". Luxembourg....
• [5] Aimmune Therapeutics, Inc.. (8/31/20). "Press Release: Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science". Brisbane, CA....
• [6] Seres Therapeutics, Inc.. (8/17/20). "Press Release: Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock". Cambridge, MA....
• [7] Aimmune Therapeutics, Inc.. (2/5/20). "Press Release: Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science". Brisbane, CA....
• [8] Seres Therapeutics, Inc.. (3/6/19). "Press Release: Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates". Cambridge, MA....
• [9] Aimmune Therapeutics, Inc.. (2/28/19). "Press Release: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights". Brisbane, CA....
• [10] Codexis, Inc.. (2/14/19). "Press Release: Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria". Redwood City, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.